These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N; Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346 [TBL] [Abstract][Full Text] [Related]
30. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Pho L; Grossman D; Leachman SA Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187 [TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B; J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071 [TBL] [Abstract][Full Text] [Related]
33. Novel and recurrent p14 mutations in Italian familial melanoma. Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244 [TBL] [Abstract][Full Text] [Related]
34. CDKN2A mutations in multiple primary melanomas. Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223 [TBL] [Abstract][Full Text] [Related]
35. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796 [TBL] [Abstract][Full Text] [Related]
36. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. Ghiorzo P; Bonelli L; Pastorino L; Bruno W; Barile M; Andreotti V; Nasti S; Battistuzzi L; Grosso M; Bianchi-Scarrà G; Queirolo P Exp Dermatol; 2012 Sep; 21(9):718-20. PubMed ID: 22804906 [TBL] [Abstract][Full Text] [Related]
37. Molecular pathogenesis of cutaneous melanocytic neoplasms. Ibrahim N; Haluska FG Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696 [TBL] [Abstract][Full Text] [Related]
38. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Goldstein AM; Martinez M; Tucker MA; Demenais F Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):889-94. PubMed ID: 11008905 [TBL] [Abstract][Full Text] [Related]
39. [From gene to disease; from p16 to melanoma]. Gruis NA; Bergman W Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670 [TBL] [Abstract][Full Text] [Related]
40. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]